Rx License-Rx

15-7496-tpNCS

Selective phagocytosis of human cancer cells as target for immunotherapy

Cell therapy based methods to reduce tumor growth by disrupting the CD47-SIRPα interaction and targeting cells for phagocytosis with antibodies. Problem: Current cancer treatments (i.e. radiation, chemotherapy, etc.) result in multiple serious side effects due to lack of treatment specificity. Cancer immunotherapies in development target the CD47-SIRPα interaction in order to incite local macrophages to engulf cancer cells, but tumor associated macrophages in solid tumors do not exhibit strong anti-tumor properties. In addition, CD47 is abundant on all healthy cells, so that targeting CD47 will generally harm healthy cells and lead to a variety of unwanted side effects such as anemia. A therapy that enhances macrophage phagocytosis specifically of tumor cells and also avoids broad targeting of CD47 will reduce tumor size without the complications of current treatment regimens. Solution: The Discher Lab has developed a method to...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Cancer

Modality: Cell/Gene Therapy

Focus tags: Oncology, Immunology

Technology tags: Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: US 12,421,495 US 10,946,042

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Cancer. Public description: Cell therapy based methods to reduce tumor growth by disrupting the CD47-SIRPα interaction and targeting cells for phagocytosis with antibodies. Problem: Current cancer treatments (i.e. radiation, chemotherapy, etc.) result in multiple.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Cancer

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.